HIKMA - 2008 Preliminary Results Interview With CEO

LONDON - Hikma Pharmaceuticals today announced strong revenue growth and stable
net profits despite a loss at the company’s US Generics business. The
weakness in the US was offset by a strong performance from the multinational
Pharma company’s Injectable and Branded businesses. CEO, Said Darwazah, said
“The US operations, in 2007, reported operating profit of about $30m and in
2008 we had a loss there so in spite of this $30m plus loss the other
divisions, the Branded and the Injectables, performed so well, grew so much
that they were able to offset that.”

Noting the current macro economic downturn Mr Darwazah said Hikma’s
diversified business model, both by geography and product, would support
growth in 2009. “It’s going to be a very, very tough year. And the way we’re
going to address this, as we said, is by controlled growth. Growth of 10% to
15%.”

It’s free to view. All you need to do is register at
www.cantos.com. Cantos.com, the online financial broadcaster, features
in-depth interviews, documentaries and webcasts with senior company
executives. If you would like to contact us, please email
enquiries@cantos.com or phone +44-207-936-1333.

Source: HIKMA

If you would like to contact us, please email enquiries at cantos.com or phone +44-207-936-1333